Market Intelligence, Clinical Progress, and High-Purity Reagents for Thrombotic Thrombocytopenic Purpura (TTP) Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ADAMTS13 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Enzyme (WT & Mutants) | ADAMTS13 Full-Length & MDTCS Truncation Protein. HEK293 Expressed (Native Glycosylation), High Purity (>95%), Endotoxin <1EU/ug. Sequence Verified. | View ADAMTS13 Products |
| Mutant Controls | ADAMTS13 E225Q (Catalytic Dead) & cTTP Patient Mutants (e.g., Q456H, R692C). Theoretical MW confirmed. For mechanism studies and assay controls. | View ADAMTS13 Products |
| Gene Delivery | ADAMTS13 Lentivirus Premade Particles or Promise-ORF. Full-length ORF for stable cell line construction. | View ADAMTS13 Products |
| Benchmark Ab | Anti-ADAMTS13 Monoclonal (C-terminal/Middle Domains). For PK/ADA assays and immunocapture. Recombinant, endotoxin controlled. | View ADAMTS13 Products |
| Validator | ADAMTS13 siRNA Set (3 unique sequences). For knockdown validation in expression studies. Sequence-verified. | View ADAMTS13 Products |
| Related Target: vWF | von Willebrand Factor (vWF). Native substrate for activity assays (FRETS-vWF73). Critical for functional validation. | View von Willebrand Factor Products |
| Related Target: GP1BA | Glycoprotein Ib alpha (GP1BA). Platelet receptor mediating vWF-platelet interaction. Downstream efficacy marker. | View GP1BA Products |
| Related Target: CD36 | Scavenger receptor implicated in clearance of ADAMTS13; critical for half-life optimization. | View CD36 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Maintaining Native Conformation & Enzymatic Activity | HEK293-expressed ADAMTS13 with native human glycosylation; >95% purity by SDS-PAGE/HPLC; Sequence verified. |
| Autoantibody/Inhibitor Screening (iTTP Diagnostics) | High-purity full-length antigen for ELISA/SPR; E225Q catalytic dead mutant for non-cleavage binding controls; endotoxin <1 EU/ug. |
| Immunogenicity Assessment (PK/ADA) | Anti-ADAMTS13 antibodies with confirmed cross-reactivity to human/cynomolgus; low endotoxin for cell-based assays. |
| Preclinical Species Translation | Human, cynomolgus, and mouse ADAMTS13 orthologs available, sequence-verified domain conservation. |
| Assay Controls (Knockdown, Specificity) | Sequence-verified siRNA set (3 sequences) and benchmark monoclonal antibodies included as reference standards. |
Key Functional Domains & Clinically Relevant Mutations
ADAMTS13 comprises several functional domains: Peptidase M12B (metalloprotease domain) responsible for catalytic activity, a Disintegrin domain, and Thrombospondin type-1 (TSP1) repeats (e.g., TSP type-1 1). These domains mediate substrate recognition and interaction with von Willebrand factor.
Key mutations identified in the target:
- rs34024143: does not affect protein secretion.
- rs281875297: associated with thrombotic thrombocytopenic purpura (TTP).
- rs281875302: reduces protein secretion and proteolytic activity; associated with TTP.
These genetic variants are critical for understanding disease mechanisms and for designing appropriate assay controls.
Global Clinical Landscape & Future Outlook
The ADAMTS13 therapeutic landscape is transitioning from acute crisis management to preventive enzyme replacement and curative gene editing. With Takeda's recombinant ADAMTS13 (TAK-755, apadamtase alfa) securing approval in Japan (2024) and advancing through global regulatory pathways, the standard of care for congenital TTP (cTTP) is shifting toward prophylactic biologics. Concurrently, CRISPR Therapeutics and Vertex are pioneering in vivo gene editing (CTX311), aiming for single-dose functional cure. For acquired TTP (aTTP), the dominance of anti-vWF therapies (Sanofi's Caplacizumab) has elevated ADAMTS13 activity monitoring from a diagnostic tool to a critical pharmacodynamic biomarker. The next wave of R&D targets engineered autoantibody-resistant variants (to evade inhibitors in iTTP), long-acting Fc-fusions for subcutaneous administration, and next-generation gene therapy delivery mechanisms, driving demand for highly standardized assay reagents.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Recombinant Enzyme Replacement (rERT) | Takeda (TAK-755 / Apadamtase alfa), Bayer | cTTP, aTTP | PK/ADA Detection; Enzyme Activity Assay (Need high-purity antigen & properly folded protein) |
| In Vivo Gene Therapy | CRISPR Tx / Vertex (CTX311), Various | cTTP | Expression Validation (Need anti-ADAMTS13 antibodies for IHC/Western) |
| FcRn Inhibitors (Autoantibody clearance) | Rigel, Immunovant | aTTP | ADAMTS13 Activity Monitoring (Need functional enzyme and vWF substrate) |
| Anti-vWF Nanobody | Sanofi (Caplacizumab) | aTTP | ADAMTS13 Level Surveillance (Need sensitive antigen detection) |
| Engineered Variants (Immune Evasion) | Early-stage Biotechs | iTTP (Refractory) | Epitope Mapping (Need high-purity mutant panel to test immune evasion) |
| Diagnostics (IVD) | In Vitro Diagnostic Companies | iTTP Autoantibody Detection | High-Spec Antigen (Need sequence-verified WT ADAMTS13 for ELISA coating) |
Live ADAMTS13 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly: